Company intelligence / Profile preview

Optimvia

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Optimvia has developed a novel enzymatic method to synthesize heparin without relying on animal sources. The process has been demonstrated at small scale and the company has partnered with Ginkgo Bioworks to scale up production. No clinical results reported as of March 2025.

Therapeutic areas: Cardiovascular
Modalities: Enzyme-based therapySmall moleculeBiologic
Industry: Non-Drug Biotech

Partnerships

Ginkgo Bioworks

Beyond the preview

Go deeper on Optimvia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optimvia.

Explore the full profile